Biotechnology
Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2
- Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2 - Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed - Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease HEIDELBERG, Germany and C...
2021-04-28 20:00
1578
CROs dMed and Clinipace Merge to Accelerate Customer Success
SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...
2021-04-28 20:00
3035
Turn Biotechnologies completes latest round of funding
Silicon Valley investor Khosla Ventures joins esteemed group of global investors backing Turn MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest...
2021-04-28 19:50
2739
GenScript Launches Research-Grade Lentiviral Vector Packaging Service
PISCATAWAY, N.J., April 28, 2021 /PRNewswire/ -- GenScript®
2021-04-28 19:30
2459
Samsung Biologics Reports First Quarter 2021 Financial Results
* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit of KRW 74.3 billion increased 19% compared to Q1'20. * Q1'21 operating margin held steady at 28%. * All manufacturing facilities remain fully operational, without any disruptions caused by the COV...
2021-04-28 16:37
4491
TCI Co., Ltd. becomes Asia's first biotechnology company whose climate ambitions are validated by SBTi
TAIPEI, April 27, 2021 /PRNewswire/ -- TCI Co., Ltd. (8436. TWO), the leading nutraceutical ODM company, announced onApril 22nd that it is finally, after six months of review, recognized by the Science Based Targets Initiative (SBTi) as "committed" to aligning its actions to reduce greenhouse ...
2021-04-27 15:53
2084
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...
2021-04-27 09:23
2313
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PROVIDENCE, R.I., April 27, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" inFrontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administrati...
2021-04-27 09:00
3205
Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer
SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...
2021-04-26 22:08
2377
PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
DAEJEON, South Korea, April 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for ...
2021-04-26 20:00
1594
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center...
2021-04-26 19:00
1814
One-Stop CLIA Solution with Open Systems and Resources Makes Evolution to Emerging World Healthcare Systems
* Advanced, flexible cooperation models delivered by one-stop CLIA solution can boost government industrialization plans, laboratory technology updates, reagent R&D and localization, and even more investment flows to the industry * COVID-19 NAb Test CLIA Solution coupled with COVID-19 Ag Self ...
2021-04-26 15:17
2079
Associates of Cape Cod, Inc. announces launch of PyroSmart NextGen™ Recombinant LAL Reagent
EAST FALMOUTH, Mass., April 23, 2021 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC), a Seikagaku Group Company, announces the launch of a new, innovative, sustainable recombinant LAL reagent, PyroSmart NextGen™ for Bacterial Endotoxin Testing (BET). The new LAL reagent is sustainably produced...
2021-04-23 22:30
4128
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
Given universal eligibility and broad availability of COVID-19 vaccines in the U.S., DoD JPEO-CBRND has notified INOVIO that it will discontinue funding for the Phase 3 INO-4800 trial INOVIO adjusts INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs PLYMOUTH ...
2021-04-23 20:00
4724
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...
2021-04-23 15:00
2069
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...
2021-04-22 21:47
3370
Wuxi Strives to Build a World-class Biomedical Industry Chain
WUXI, China, April 22, 2021 /PRNewswire/ -- From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi,China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and dialogue...
2021-04-22 19:06
1093
RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt
MOSCOW, CAIRO and BERLIN, April 22, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF,Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and itsBerlin-based subsidiary, ProBioGen AG, announce the agreement to produce over 40 million ...
2021-04-22 16:00
2658
Clarivate Releases Predictive Analytics to Help Fuel Life Sciences Deal Making Landscape
Cortellis Deals Intelligence features new trends visualizations and predictive analytics supported by artificial intelligence LONDON, April 22, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, t...
2021-04-22 16:00
3549
endpoint Launches ConnectionPOINT™ - A partnership program designed to power accelerated outcomes and move medicine through next-generation eClinical technology interfacing
SAN FRANCISCO, April 21, 2021 /PRNewswire/ -- endpoint Clinical, the leading global interactive response technology (IRT®) company, announced today the launch of their partnership program,ConnectionPOINT™, the first of its kind in the eClinical technology space. The program's vision is for a g...
2021-04-21 21:00
3123
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6494
